Summary
Global Markets Direct’s, ‘RXi Pharmaceuticals Corporation - Product Pipeline Review - 2016’, provides an overview of the RXi Pharmaceuticals Corporation’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by RXi Pharmaceuticals Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of RXi Pharmaceuticals Corporation
- The report provides overview of RXi Pharmaceuticals Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses RXi Pharmaceuticals Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features RXi Pharmaceuticals Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate RXi Pharmaceuticals Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for RXi Pharmaceuticals Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RXi Pharmaceuticals Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
RXi Pharmaceuticals Corporation Snapshot 6
RXi Pharmaceuticals Corporation Overview 6
Key Information 6
Key Facts 6
RXi Pharmaceuticals Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
RXi Pharmaceuticals Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
RXi Pharmaceuticals Corporation - Pipeline Products Glance 12
RXi Pharmaceuticals Corporation - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
RXi Pharmaceuticals Corporation - Early Stage Pipeline Products 14
IND/CTA Filed Products/Combination Treatment Modalities 14
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
RXi Pharmaceuticals Corporation - Drug Profiles 17
diphencyprone 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
RXI-109 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
RNAi Oligonucleotide to Inhibit CTGF for PVR 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
RNAi Oligonucleotide Inhibiting MDM2 for Retinoblastoma 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
RNAi Oligonucleotide to Inhibit SOD-1 for ALS 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RNAi Oligonucleotide to Inhibit VEGF for Macular Degeneration 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RXI-209 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
bevasiranib sodium 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MMP-26051 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MMP-26052 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RNAi Oligonucleotide to Inhibit Angiopoietin-2 for Retinal Disease and Cancer 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Cancer 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
RNAi Oligonucleotide to Inhibit ICAM-1 for Retinal Diseases and Cancer 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RNAi Oligonucleotides to Inhibit Complement C3 for Ophthalmology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
RNAi Oligonucleotides to Inhibit TNF-alpha for Autoimmune Disorders 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TRY-26071 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TRY-26077 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
RXi Pharmaceuticals Corporation - Pipeline Analysis 37
RXi Pharmaceuticals Corporation - Pipeline Products by Target 37
RXi Pharmaceuticals Corporation - Pipeline Products by Route of Administration 39
RXi Pharmaceuticals Corporation - Pipeline Products by Molecule Type 40
RXi Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action 41
RXi Pharmaceuticals Corporation - Recent Pipeline Updates 43
RXi Pharmaceuticals Corporation - Dormant Projects 51
RXi Pharmaceuticals Corporation - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
bevasiranib sodium 52
RXi Pharmaceuticals Corporation - Locations And Subsidiaries 53
Head Office 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55
List of Tables
RXi Pharmaceuticals Corporation, Key Information 6
RXi Pharmaceuticals Corporation, Key Facts 6
RXi Pharmaceuticals Corporation - Pipeline by Indication, 2016 8
RXi Pharmaceuticals Corporation - Pipeline by Stage of Development, 2016 10
RXi Pharmaceuticals Corporation - Monotherapy Products in Pipeline, 2016 11
RXi Pharmaceuticals Corporation - Phase II, 2016 12
RXi Pharmaceuticals Corporation - Phase I, 2016 13
RXi Pharmaceuticals Corporation - IND/CTA Filed, 2016 14
RXi Pharmaceuticals Corporation - Preclinical, 2016 15
RXi Pharmaceuticals Corporation - Discovery, 2016 16
RXi Pharmaceuticals Corporation - Pipeline by Target, 2016 37
RXi Pharmaceuticals Corporation - Pipeline by Route of Administration, 2016 39
RXi Pharmaceuticals Corporation - Pipeline by Molecule Type, 2016 40
RXi Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action, 2016 41
RXi Pharmaceuticals Corporation - Recent Pipeline Updates, 2016 43
RXi Pharmaceuticals Corporation - Dormant Developmental Projects,2016 51
RXi Pharmaceuticals Corporation - Discontinued Pipeline Products, 2016 52
List of Figures
RXi Pharmaceuticals Corporation - Pipeline by Top 10 Indication, 2016 8
RXi Pharmaceuticals Corporation - Pipeline by Stage of Development, 2016 10
RXi Pharmaceuticals Corporation - Monotherapy Products in Pipeline, 2016 11
RXi Pharmaceuticals Corporation - Pipeline by Top 10 Target, 2016 37
RXi Pharmaceuticals Corporation - Pipeline by Route of Administration, 2016 39
RXi Pharmaceuticals Corporation - Pipeline by Molecule Type, 2016 40
RXi Pharmaceuticals Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016 41
